<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>

<![CDATA[FDA Approves Subcutaneous Isatuximab in Multiple Myeloma]]>

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma

The FDA approved the subcutaneous (SC) administration of the anti-CD38 antibody isatuximab-irfc (Sarclisa) in multiple myeloma, based on non

Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for ...

Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDA Today, July 9, 2026, the U.S. FDA "approved

<![CDATA[Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma]]>

<![CDATA[Relapsed/Refractory Multiple Myeloma: Interpreting MonumenTAL-3 Efficacy and Safety Findings]]>

FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma

FDA approved Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation of Sanofi's Sarclisa, for the treatment of multiple myeloma acros